Open Access
Review

Sarcopenia and perioperative management of elderly surgical patients

Yan Shi1,†,Ling Zhou1,†,Enshi Yan2,Ling Yang3,Chun Yang1,*,Cunming Liu1,*
1
Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu, China
2
Department of Anesthesiology, Affiliated Stomatological Hospital, Nanjing Medical University, 210029 Nanjing, Jiangsu, China
3
Department of Cardiology, The Third Affiliated Hospital of Soochow University, 212003 Changzhou, Jiangsu, China
DOI: 10.52586/4995 Volume 26 Issue 10, pp.882-894
Submited: 18 July 2021 Revised: 12 September 2021
Accepted: 16 September 2021 Published: 30 October 2021
*Corresponding Author(s):  
Chun Yang
E-mail:  
chunyang@njmu.edu.cn
*Corresponding Author(s):  
Cunming Liu
E-mail:  
cunmingliu@njmu.edu.cn
† These authors contributed equally.
Copyright: © 2021 The author(s). Published by BRI. This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

Sarcopenia is the age-related loss of skeletal muscle mass, accompanied by reduced muscle strength or physical function. As the global population continues to age, the prevalence of sarcopenia is gradually increasing. It is conceivable that an increasing number of patients with sarcopenia will be scheduled for surgery and anesthesia in the near future. The complex pathogenesis and clinical features of sarcopenia have brought huge challenges to perioperative management, especially in clinical anesthesia. However, there are currently neither guidelines nor expert consensus on the perioperative management of patients with sarcopenia. In this review, we summarize and elaborate on the pathogenesis, diagnosis, and perioperative precautions of sarcopenia, thereby providing information on the perioperative and anesthestic management of patients with sarcopenia.

Key words

Sarcopenia; Aging; Anesthesia; Anesthetic management; Review

2. Introduction

In the 1980s, Rosenberg was the first to describe sarcopenia, which was initially defined as the age-related loss of lean body mass [1]. Subsequently, the concept of sarcopenia continued to develop, and it is currently believed that the decline of muscle function has more clinical significance than the loss of muscle mass. In 2018, the revised European consensus on sarcopenia added low muscle strength to the definition of sarcopenia [2]. The Asian Working Group for Sarcopenia (AWGS) also updated their consensus in 2019, defining sarcopenia as an age-related loss of muscle mass accompanied by either or both low muscle strength and low physical performance, and classifying sarcopenia as the changes in muscle strength and physical function [3]. The prevalence of sarcopenia varies significantly due to differences in the use of diagnostic criteria and tools and in study populations. In Asia, the sarcopenic elderly account for approximately 4.1%–11.5% of the population, while European countries have significantly higher prevalence, ranging from 6.8% to 21.8% [4, 5, 6, 7, 8, 9]. With the global population aging, the prevalence of sarcopenia will gradually increase. It is estimated that by 2050, more than 200 million patients will have sarcopenia, and this estimate has attracted the attention of clinicians [10]. In 2016, sarcopenia was recognized as an independent disease with its own International Classification of Diseases, Tenth Revision, Clinical Modification code (M62.84) [11].

The development of sarcopenia is not limited to elderly lean patients, patients with obesity may also have sarcopenia [12]. It is often believed that the presence of both sarcopenia and obesity can be diagnosed as sarcopenic obesity, although there is currently no uniform definition of sarcopenic obesity. A study applied dual-energy X-ray absorptiometry (DXA) to analyze the body compositions of 4984 patients showed that the prevalence of sarcopenic obesity in men and women were 12.6% and 33.5%, respectively [13]. Interestingly, the prevalence gradually increases with age.

As the average life expectancy increases, the prevalence of sarcopenia was gradually increased. Studies have shown that the pathophysiological changes caused by sarcopenia and aging can significantly increase the risk of perioperative adverse events, including adverse cardiovascular events, adverse drug reactions, severe postoperative complications, prolongation of hospital stay, surgical failure, and even high mortality [14, 15, 16]. However, unlike aging, sarcopenia can be modified before surgery, thereby reducing the incidence of perioperative adverse events and significantly improving the clinical outcomes of such elderly patients. Therefore, the diagnosis, treatment, and perioperative management of elderly sarcopenic patients will be the focus of clinicians in the near future. Regrettably, there are currently no guidelines or clinical recommendations for the perioperative management of patients with sarcopenia. This review will elaborate on the diagnosis, pathogenesis, treatment and perioperative management of sarcopenia, so as to provide reasonable suggestions for clinicians to develop individualized anesthetic management plans.

3. Diagnosis of sarcopenia

There are strong correlations between sarcopenia and falls, disability, adverse outcomes, and mortality in the elderly, so the early diagnosis of sarcopenia is particularly important [17]. In clinical practice, we comprehensively evaluate muscle strength, physical function, and muscle mass in order to make a correct diagnosis for elderly patients according to an algorithm (Fig. 1). Because measuring handgrip strength is simple and easy, it is a recommended method with which to measure muscle strength. Gait speed is the clinical test most commonly used to assess physical performance. At present, the main methods used to estimate muscle mass include computed tomography (CT) scan, magnetic resonance imaging (MRI), bioelectrical impedance analysis (BIA), and other imaging techniques. Although CT and MRI are the gold standards for assessing muscle mass, they are relatively expensive and lack precise diagnostic cut-offs; therefore, they are not commonly used in clinical practice [18]. DXA and BIA are inexpensive, safe, and convenient, so the European Working Group on Sarcopenia in Older People (EWGSOP) and AWGS recommend the use of DXA or BIA for muscle mass determination and provide diagnostic cut-offs [2, 3]. However, the precarious conditions of critically ill patients and the relatively limited time before surgery make these examinations impractical for intensive care unit (ICU) physicians and anesthesiologists. Therefore, Mueller et al. [19] proposed using ultrasounds to assess and diagnose sarcopenia in critically ill patients. Although the effectiveness of ultrasounds in measuring muscle mass has been proven, the EWGSOP does not recommend using an ultrasound as a diagnostic tool due to the lack of standardized measurement methods and prediction equations [2, 20]. In addition, for the diagnosis of sarcopenia, the exploration of biomarkers is very meaningful, allowing an anesthesiologist to find patients with sarcopenia conveniently and quickly through laboratory records during preoperative visits. Several biomolecules are confirmed to be related to the onset of sarcopenia, including myostatin, irisin, sarcopenia index (serum creatinine/serum cystatin C), and so forth [21]. However, due to the lack of diagnostic criteria, these are still not widely evaluated in clinical practice.

 ASM, appendicular skeletal muscle mass; AWGS, Asian Working Group for Sarcopenia; BIA, bioelectrical impedance analysis; DXA, dual-energy X-ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People; F, female; M, male; SPPB, Short Physical Performance Battery; TUG, timed-up-and-go.

Figure 1: Algorithms for the diagnosis of sarcopenia. ASM, appendicular skeletal muscle mass; AWGS, Asian Working Group for Sarcopenia; BIA, bioelectrical impedance analysis; DXA, dual-energy X-ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People; F, female; M, male; SPPB, Short Physical Performance Battery; TUG, timed-up-and-go.

4. Pathogenesis of sarcopenia

4.1 Neuromuscular degeneration

Neuromuscular degeneration plays an important role in the occurrence and development of sarcopenia, and is mainly characterized by motor unit remodeling and neuromuscular junction degeneration [22, 23]. The motor unit is composed of α motor neurons in the anterior horn of the spinal cord and of the skeletal muscle fibers innervated by them. In the aging process, the progressive decrease of α motor neurons leads to denervation of muscle fibers, and the remaining motor neurons send out collaterals for reinnervation [24, 25]. When the nerve reinnervation is not enough to compensate for the damage caused by denervation, the patient experiences muscle atrophy and hypofunction. Satellite cells are muscle-derived stem cells with proliferation abilities in the skeletal muscle, and they play an important role in muscle regeneration and damage repair [26]. In the aging process, atrophy is more pronounced in type II muscle fiber than in type I muscle fiber [27]. Moreover, the number of type II muscle fiber satellite cells decreases with increasing age, and the remaining cells have reduced regeneration and repair functions, which further aggravates the muscle fiber atrophy after denervation and causes a reduction in muscle volume [28, 29]. As a chemical synapse, the neuromuscular junction can convert the electrical impulse of the motor nerve into a muscle contraction. The neuromuscular junction also undergoes a variety of morphological and functional changes during the aging process, including a decrease in the number of acetylcholine receptors, fragmentation of the endplate, and a decrease in the number of postsynaptic folds, which together ultimately causes the failure of neuromuscular junction transmission [30]. More importantly, the instability of the neuromuscular junction structure and function is an important cause of sarcopenia (Fig. 2) [31].

 AChRs, acetylcholine receptors; GH, growth hormone; IGF-1, insulin-like growth factor-1; IL-1, interleukin 1; IL-6, interleukin 6; NMJ, neuromuscular junction; TNF-

Figure 2: Schematic representation of the main factors involved in the progression of sarcopenia. AChRs, acetylcholine receptors; GH, growth hormone; IGF-1, insulin-like growth factor-1; IL-1, interleukin 1; IL-6, interleukin 6; NMJ, neuromuscular junction; TNF-α, tumor necrosis factor-alpha.

4.2 Mitochondrial dysfunction

Although the exact pathogenesis of sarcopenia is still unclear, mitochondrial dysfunction, especially impairments in the mitochondrial quality control (MQC) pathway, plays a major role in the course of sarcopenia [32, 33]. MQC is defined by mitophagy and mitochondrial biogenesis, a mechanism that maintains mitochondrial morphology and function through mitochondrial fusion/fission [34, 35]. Mitochondrial fusion can redistribute protein and mitochondrial DNA, exchanging material and energy to meet the body’s needs [36]. Alternatively, fusion can reduce the concentration of damaged substances to maintain the normal functions of the mitochondria [37]. Fission can isolate severely damaged mitochondria and clear them through autophagy to avoid excessive accumulation of dysfunctional mitochondria and reduce the generation of reactive oxygen species (ROS) [38]. Mitochondria form a complex mitochondrial network through continuous fusion and fission (i.e., mitochondrial dynamics), which plays an important role in maintaining muscle morphology and contraction function [39]. With the appearance of aging, the MQC pathway appears abnormal, displaying disturbed mitochondrial dynamics, decreased mitophagy, and reduced mitochondrial biogenesis [40, 41, 42, 43]. Unbalanced mitochondrial dynamics and reduced mitophagy cause mitochondrial dysfunction, damage the mitochondrial network, and ultimately lead to skeletal muscle loss and muscle function decline [39]. At the same time, dysfunctional mitochondria continue to accumulate, leading to reduced adenosine triphosphate production and excessive ROS production. In turn, the increased production of ROS causes electron transport chain damage and mitochondrial DNA mutations, and then further aggravates mitochondrial dysfunction, forming a vicious circle, which finally results in the deterioration of skeletal muscle quality and function [33, 44]. On the other hand, excessive ROS reduces the sensitivity of the anabolic signaling pathway mediated by insulin-like growth factor-1 (IGF-1) and activates skeletal muscle proteolytic signaling pathways, which cause decreased muscle protein synthesis and increased protein breakdown. These changes ultimately promote the occurrence and development of sarcopenia [45, 46, 47]. In addition, mitochondrial dysfunction can cause neuromuscular junction remodeling and the loss of motor units [48]. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1α) is an important regulator of mitochondrial biogenesis, which promotes mitochondrial biogenesis and quality control by regulating downstream transcription factors [49]. The overexpression of PGC-1α can prevent muscle atrophy, whereas knocking out PGC-1α leads to decreased muscle mass and function [50, 51]. The expression of PGC-1α in the skeletal muscle is significantly reduced as one ages, which may be an important cause of sarcopenia [52].

4.3 Inflammaging

In the process of aging, patients often have low-grade, systemic chronic inflammation without corresponding clinical symptoms: that is, “inflammaging” [53]. These inflammatory factors include but are not limited to tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), interleukin 1 (IL-1), TNF-α like weak inducer of apoptosis (TWEAK), and C-reactive protein [54, 55]. Cross-sectional studies have shown that increased levels of inflammatory cytokines, especially TNF-α and TWEAK, are positively correlated with both the severity and risk of sarcopenia in elderly patients, further indicating that chronic inflammation may be involved in the occurrence and development of sarcopenia [54]. TNF-α can activate the ubiquitin-proteasome pathway (the main pathway of skeletal muscle protein degradation) through nuclear factor-κB (NF-κB) to increase Muscle Ring Finger 1 expression and can lead to atrokin-1 expression independent of NF-κB activation [56]. Inflammatory cytokines can also antagonize the effects of protein synthesis caused by IGF-1. The increased degradation and decreased synthesis of skeletal muscle protein ultimately leads to the destruction of protein homeostasis and muscle atrophy. Inflammatory cytokines can also reduce the regeneration function of muscle satellite cells, further promoting the development of sarcopenia [57]. There is also a proposed role of the relationship between inflammation and mitochondria in sarcopenia. Inflammatory cytokines cause mitochondria to produce excessive ROS, decrease the expression of PGC-1α, damage the electron transport chain, and inhibit mitophagy, eventually leading to MQC derangements, aggravating the impairment of muscle mass and strength [58, 59, 60, 61].

4.4 Sarcopenic obesity

Currently, sarcopenic obesity is defined as the coexistence of obesity and sarcopenia [62]. However, the pathogenesis of sarcopenic obesity is not a simple superposition of the mechanisms of these comorbidities. Obesity and sarcopenia may have some common pathogenesis and may aggravate each other [63]. In the aging process, due to the changes in hormone levels (including decreased levels of estrogen, testosterone, growth hormone, and IGF-1) and a decrease in physical activity, the resting metabolic rate is reduced, which leads to a decrease in protein synthesis and a progressive increase in fat mass [12]. The existence of sarcopenia further reduces the activity levels of elderly patients and aggravates fat accumulation [64]. Fat accumulates abnormally in adipose tissue, after which immune cells infiltrate the tissue and release a large number of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1 [65]. These inflammatory molecules enter the circulatory system to cause systemic inflammation and promote inflammaging [63]. Excess fatty acids can also accumulate ectopic lipids in skeletal muscle, attracting immune cells that infiltrate the muscles and produce local inflammation, leading to muscle dysfunction [66]. Additionally, lipids and their derivatives in muscle cells further reduce the mitochondrial β-oxidation capacity and increase the production of ROS, causing lipotoxicity and thereby reducing muscle strength [32, 67, 68]. Intramyocellular fat accumulation and subsequent mitochondrial dysfunction lead to skeletal muscle insulin resistance, further interfere with the metabolic homeostasis of skeletal muscle, and promote muscle breakdown [69, 70].

5. Treatment of sarcopenia

5.1 Physical exercises

Sarcopenia is associated with falls, disability, longer hospital stays, and mortality in the elderly, so treatment strategies should be initiated immediately when sarcopenia is diagnosed [17]. Currently, the treatment of sarcopenia mainly includes physical exercises, nutritional supplementation, and pharmacological interventions. Physical exercises are currently considered to be the most effective of these treatment options [71]. Physical exercises can significantly increase muscle mass, improving the muscle function and physical performance [72, 73]. Exercise interventions mainly include resistance training and endurance training. The current focus is mainly on resistance training. Resistance training can inhibit mitochondrial-mediated apoptosis and regulate the IGF-1/Akt/mammalian target of the rapamycin signaling pathway, thereby promoting protein synthesis [74]. A meta-analysis of 14 trials showed that there is high-quality evidence that resistance training can improve muscle mass, strength, and physical performance [75]. Importantly, high-intensity training may provide greater benefits than other exercises. An 18-month randomized controlled study involving 43 participants confirmed that high-intensity resistance exercise can increase the skeletal muscle mass and grip strength of patients with sarcopenia and can inhibit the progression of sarcopenia [76]. Endurance training can also improve mitochondrial function by increasing PGC-1α, increase insulin sensitivity, and promote anabolism by increasing the levels of growth hormone and IGF-1 in the circulation, thus preventing and treating sarcopenia [74, 77]. However, there is no consensus on the optimal exercise frequency, intensity, or mode, which should be examined by future clinical research.

5.2 Nutrition

Although exercise is an effective measure with which to intervene in sarcopenia, it requires professional guidance and is often difficult for the elderly to maintain. Therefore, more and more researchers are turning their attention to nutritional interventions and pharmacological approaches. Nutritional interventions mainly include supplementation of protein, vitamin D, creatine monohydrate, and so forth. [78]. Protein and vitamin D supplementation can significantly improve muscle strength and function [79, 80]. A multicenter randomized controlled trial involving 1240 elderly people showed that vitamin D and leucine can significantly improve the muscle mass and function of patients with sarcopenia [81]. However, as the optimal dosage ranges of these nutritional supplements have not yet been determined, their clinical use has been limited. Combining exercise and nutritional supplementation is among the most promising strategies [82]. Although some trials showed that the combination is beneficial for sarcopenia, no recommendations can be proposed owing to inconsistent evidence [83]. Expert guidelines believe that the time of nutritional intake before and after exercise is critical to the increase of muscle mass [84]. Studies have found that giving nutrition after exercise can produce a good synergistic effect on muscle protein synthesis [85]. Therefore, supplementation with nutrition after exercise may be more conducive to sarcopenia. Regrettably, there is little study on the effect of nutritional intake time on sarcopenia, and some of these have not shown the benefits of supplementation with nutrition after exercise for sarcopenia. A 26-week three-arm randomized controlled trial showed that compared with whey protein pre-resistance training group, the skeletal muscle mass, functional capacity, and total strength gains of the whey protein post-resistance training group were higher, but there was no significant difference between the two groups [86]. In this regard, there is still a lack of definitive clinical evidence on the effect of nutritional intake time on sarcopenia. Further studies are still needed to provide better clinical evidence.

5.3 Drugs

There are currently no drugs for the treatment of sarcopenia. Potential therapeutic drugs mainly include testosterone, selective androgen receptor modulators, and anti-inflammatory drugs [87]. Although these drugs can partially improve muscle mass and function, most of them have side effects that greatly limit their clinical usage. Studies have shown that testosterone can increase muscle protein synthesis and myogenesis, thereby improving muscle mass and strength [88, 89]. However, long-term use of testosterone may cause various complications, such as cardiovascular and prostate diseases [47, 90]. Although selective androgen receptor agonists have fewer side effects than testosterone, they have not shown significant advantages in improving muscle mass and function [91]. Therefore, testosterone is still the most effective and safest drug for sarcopenia. There is great potential for treating sarcopenia by repurposing drugs, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. A study enrolling 130 participants showed that compared with placebo, perindopril significantly improved the 6-min walking distance and physical functions of the elderly [92]. However, whether it can achieve definite curative effects in the treatment of sarcopenia still needs further verification.

6. Sarcopenia and perioperative management

6.1 Preoperative assessment

With the population aging, there is an increasing demand for surgical procedures among the elderly. However, due to sarcopenia’s comorbidities, the benefits may not outweigh the complications of surgery and anesthesia for such patients, and surgery may even cause a serious decline in the quality of life. Increasing evidence indicates that sarcopenia is closely related to postoperative complications, mortality, and lengths of hospital stays [93, 94]. Fukuda et al. [95] found in a cohort study that although there was no significant difference between sarcopenia and non-sarcopenia groups in the overall incidence of complications after gastric cancer surgery, the incidence of serious complications was significantly higher in the sarcopenia group. A multivariate analysis suggests that sarcopenia is a risk factor for severe postoperative complications. In 2018, a meta-analysis of 29 studies involving 7176 patients also showed that sarcopenia is an independent predictor of an increased risk of complications after gastrointestinal tumor resection [96]. Therefore, elderly patients with sarcopenia who need surgery should attract the special attention of anesthesiologists. At present, an American Society of Anesthesiologists (ASA) classification is often used in clinical practice to assess the risk of anesthesia in perioperative patients. However, the ASA class is mainly based on the subjective judgment of the anesthesiologist, lacks relatively objective indicators, and may not be used to predict the risks of postoperative complications, mortality, and other outcomes. [97]. The combination of the ASA classification and other objective indicators can effectively assess the patient’s baseline functional status and predict perioperative risks [98]. In addition, because of the obesity characteristics of patients with sarcopenic obesity, anesthesiologists may ignore the coexisting sarcopenia and follow the guidelines for the anesthetic management of ordinary obese patients, which may lead to serious consequences. Therefore, it is particularly important to identify and diagnose sarcopenia before surgery. The 2019 expert guidelines on liver transplantation also recommend that a sarcopenia assessment should be included in the preoperative liver transplantation evaluation [99]. On one hand, preoperative sarcopenia screening can combine an ASA classification with objective indicators of sarcopenia to effectively stratify patients before surgery, guiding clinicians in decision-making and in formulating the best anesthesia plan. On the other hand, appropriate interventions (including nutrition and exercise, among others) should be carried out during the perioperative period to increase the functional reserve of a patient with sarcopenia, thereby improving the postoperative clinical course. A study showed that after a preoperative exercise and nutritional support program (i.e., prehabilitation), 4 patients in an experimental group became non-sarcopenic, and even no patients in the sarcopenia group had a higher grade of Clavien–Dindo classification or a higher incidence of postoperative complications [100]. Therefore, it is necessary to routinely perform sarcopenia screens for patients’ 60 years old or 65 years old before surgery. This can provide valuable information for anesthesiologists to use when formulating individualized management plans for patients, thereby reducing the risk of anesthesia and improving the prognosis.

6.2 Perioperative management

6.2.1 Anesthesia protocols

Perioperative anesthesia management for elderly patients with sarcopenia is a huge challenge owing to their reduced functional reserves, comorbidities, cognitive impairments, and advanced age. One of the first issues that must be faced is the choice of an anesthesia method. There is a dispute as to whether regional anesthesia or general anesthesia is better. A study enrolling 96,289 patients aged 65 years or older who underwent hip fracture surgery showed that after propensity score matching, the mortality rate, delirium rate, and incidence of ICU admission in the regional anesthesia group were significantly lower than those in the general anesthesia group [101]. Therefore, the authors believe that regional anesthesia is more suitable for elderly patients. Subsequent studies also confirmed that regional anesthesia is associated with a reduced risk of multiple complications compared with general anesthesia when performing total hip arthroplasty surgery in frail elderly patients [102]. The International Consensus on Anaesthesia-Related Outcomes after Surgery group also recommends the use of neuraxial anesthesia during hip arthroplasty [103]. Therefore, under appropriate circumstances, regional anesthesia may be a better choice for the elderly. But this does not mean that regional anesthesia is always better than or can replace general anesthesia. There are still many studies showing that compared with general anesthesia, regional anesthesia has no significant difference in postoperative morbidity, readmission, and in-patient mortality rates [104, 105]. There is still no consensus on which anesthesia mode is more beneficial to the elderly. Some guidelines suggest that regional anesthesia can be used as a supplement to general anesthesia, thereby reducing the use of intraoperative anesthetics and opioids and improving clinical outcomes [106]. In any case, the anesthesiologist should develop an individualized anesthesia plan based on the preoperative evaluation of a patient with sarcopenia and the advantages and disadvantages of different anesthesia methods.

6.2.2 Sedative agents

The changes in the body composition of patients with sarcopenia, including decreased skeletal muscle, increased fat, and organ function declines, have impacts on the pharmacodynamics and pharmacokinetics of intravenous anesthetics [107]. Propofol is currently the most commonly used intravenous anesthetic in clinical practice. An observational study involving 40 patients showed that compared with other adult patients, the dose of propofol required for loss of consciousness was lower and the concentration of propofol in plasma was higher in those aged 65 years [108]. An important side effect of propofol is hypotension after induction. A retrospective analysis by Phillips et al. [109] found that high-dose propofol induction in elderly patients may lead to dose-dependent hypotension, which becomes more significant with age. Therefore, it is recommended that the dose of propofol should be reduced by 30%–50% (1–1.5 mg/kg) during induction of anesthesia in the elderly [110]. It is worth noting that there are data showing that even in ordinary elderly patients’ 80 years old, the dose of propofol needed for induction is still greater than the recommended dose [109]. Compared with ordinary elderly patients, patients with sarcopenia are more sensitive to adverse reactions, such as hypotension induced by excessive propofol, due to advanced age, poor physical functions, and severe declines in organ functions. Therefore, for elderly patients with sarcopenia, the recommended dose of propofol may be further reduced. Compared with propofol, etomidate has less of an effect on hemodynamics and may be more suitable for elderly sarcopenic patients [111, 112, 113]. Unfortunately, we still lack specific clinical data on the pharmacodynamics and pharmacokinetics of intravenous anesthetics for patients with sarcopenia. Future research on sarcopenia should pay more attention to this aspect. Therefore, we strongly recommended that clinical anesthesiologists routinely monitor the depth of anesthesia in patients with sarcopenia, optimize anesthetic medications, avoid overdoses, and improve the safety of anesthesia [114].

6.2.3 Volatile anesthetics

The effectiveness of volatile anesthetics is also different in patients with sarcopenia. With age, the minimal alveolar concentration (MAC) of inhaled anesthetics decreases, and the MAC of 80-year-old patients is about half that of infants. However, this is still based on data obtained in the general population, and there is a lack of relevant research on the use of volatile anesthetics in patients with sarcopenia. However, the decreased functional reserves in these patients may further increase their sensitivity to volatile anesthetics. In any case, in clinical practice, the anesthesiologist should pay attention to this change and adjust the dose of inhaled anesthetics according to end-tidal concentration monitoring [110].

6.2.4 Analgesia

Studies have shown that elderly patients are significantly more sensitive to adverse reactions to opioids. A retrospective analysis of 8855 patients showed that the risk of respiratory depression with opioids gradually increases with age [115]. Compared with healthy elderly patients, patients with sarcopenia have a more significant decline in the tolerance of opioids [116]. Therefore, perioperative analgesia in elderly patients with sarcopenia is mainly based on non-opioid analgesia [117]. Evidence supports the use of regional anesthesia for perioperative analgesia. Regional anesthesia can effectively relieve postoperative pain, reduce postoperative complications, and promote patient recovery [118]. A Cochrane systematic review conducted in 2018 found that there is high-quality evidence supporting the use of a regional blockade to effectively reduce postoperative movement pain, and there is moderate-quality evidence supporting the use of a regional blockade to reduce the risk of pneumonia [119]. In addition, the use of regional anesthesia can also significantly reduce the dosage and side effects of opioids. Leeper et al. [120] found that compared with receiving systemic analgesia, the average use of morphine was reduced by 41% in the fascia iliaca block. The guidelines also recommend the use of peripheral nerve blocks for analgesia [106]. Therefore, anesthesiologists can use regional blockades for perioperative analgesia in patients with sarcopenia, thereby reducing the use of opioids, avoiding unnecessary complications, and improving perioperative safety.

6.2.5 Neuromuscular blocking agents

Since the introduction of neuromuscular blocking agents into clinics, postoperative residual neuromuscular blockage remains a major problem that plagues clinicians. An observational study of 415 patients found that 31% had residual paralysis after surgery, and the incidence was higher, about 44%, in elderly patients [121]. In addition, hypoxia and ventilation support were frequent in the elderly group. Incomplete recovery of neuromuscular function can cause dysphagia, aspiration, and upper airway obstruction and can increase the risk of pulmonary complications. Sarcopenia not only affects the quality and function of the skeletal muscles of the limbs, but also causes atrophy of respiratory and swallowing muscles, leading to respiratory insufficiency and dysphagia [122, 123]. This may further aggravate the above-mentioned residual neuromuscular blockade-related complications and increase the risks associated with anesthesia. Therefore, neuromuscular blocking agents should be used cautiously in patients with sarcopenia. At present, the commonly used neuromuscular blocking agents mainly include rocuronium and cisatracurium. Rocuronium is a steroidal muscle relaxant that depends on liver and kidney elimination. Therefore, its pharmacokinetics is easily affected by age and liver and kidney functions. A number of studies have shown that the duration of action and the average recovery index time of rocuronium are prolonged in elderly patients, and the variability in these parameters is greater [124]. Therefore, Pietraszewski et al. [121] believe that a dose of rocuronium that is less than 30% of the recommended dose for young people is safer for the elderly. Unlike rocuronium, cisatracurium is eliminated by Hofmann degradation, which is organ-independent, making it less affected by age and liver and kidney functions [125]. Moreover, in elderly patients, the variability in the duration of action is lower after receiving 2 times the 95% effective dose (ED95) of cisatracurium compared with an equipotent dose of rocuronium or vecuronium [126]. This helps the anesthesiologist predict the recovery of neuromuscular function after the patient uses cisatracurium, which may be more important in the elderly. Studies based on healthy elderly patients indicate that aging does not affect the pharmacodynamics of muscle relaxants [127]. However, research has shown that due to the decrease in the number of nicotinic acetylcholine receptors, myasthenia gravis patients have a significant increase in sensitivity to non-depolarizing muscle relaxants, with a longer effect duration [128]. The efficacy of non-depolarizing muscle relaxants in myasthenia gravis patients is also significantly enhanced, and one-fourth of the standard intubating dose of rocuronium can achieve a complete neuromuscular block [129, 130]. In addition, the use of muscle relaxants can aggravate myasthenia gravis and cause respiratory distress [131]. The pathogenesis of sarcopenia is complicated, especially the presence of motor unit remodeling; neuromuscular junction degeneration, including a reduction in the number of acetylcholine receptors; endplate fragmentation; and reduction in postsynaptic folds, which may significantly change the pharmacological properties of muscle relaxants. In addition, due to the high risk of a residual neuromuscular blockade in patients with sarcopenia, it is particularly important to use antagonists when appropriate to completely reverse the relaxation at the end of anesthesia. The timing of administration mainly depends on the depth of the neuromuscular blockade. Therefore, in the process of anesthesia management for sarcopenic patients, it is strongly recommended that anesthesiologists use neuromuscular function monitoring, carefully titrate the dose of muscle relaxants, avoid the use of excessive muscle relaxants, and timely antagonize muscle relaxants to reduce the incidence of residual paralysis and ensure patient safety.

6.3 Anesthesia-related complications

Due to the existence of common pathophysiological mechanisms such as chronic inflammation and hormonal pathways, sarcopenia is an important risk factor for cognitive impairment and dementia. A meta-analysis of 22 studies found that sarcopenia is associated with an increased risk of cognitive impairment, and this effect is independent of the study population and the definitions used for sarcopenia and cognitive impairment [132]. An advanced age and preoperative cognitive impairment are both important risk factors for perioperative cognitive dysfunction [133]. Among the cognitive complications related to anesthesia, sarcopenia is closely related to the occurrence of postoperative delirium. Hiraoka et al. [134] found that the decreased muscle function group showed a higher incidence of postoperative delirium after liver cancer surgery. A retrospective cohort study of 251 patients found that compared with patients without a low skeletal muscle mass (LSMM), patients with an LSMM had a higher incidence of postoperative delirium [135]. A multivariate analysis showed that LSMM is associated with postoperative delirium in patients with colon cancer, and this correlation is more significant when patients also have malnutrition or physical dependence [135]. Therefore, patients with sarcopenia should be identified during the perioperative period, we should be vigilant about possible postoperative delirium, and we should take necessary measures to prevent postoperative delirium. Exercise and nutritional interventions are used to improve sarcopenia before surgery and reduce the occurrence of postoperative delirium. Multi-modal analgesia is used during the perioperative period to avoid postoperative delirium caused by insufficient analgesia or an overdose of opioids. If possible, the use of drugs that can cause postoperative delirium should be avoided or reduced during the perioperative period, including benzodiazepines, opioids, ketamine, antihistamines, and atropine [114].

7. Conclusions

The high prevalence of sarcopenia and the increasing demand for surgery have brought great challenges to clinical anesthesiologists. Due to its complex pathophysiological process, sarcopenia may cause pharmacological changes in anesthetic drugs, such as a decreased effective dose and a relatively prolonged duration of action. Therefore, in the selection of anesthesia methods and medications, it is necessary to comprehensively consider the basic conditions of patients with sarcopenia and the changes in the characteristics of anesthetic drugs and then make an individualized anesthetic management strategy. The current data are mostly based on studies of healthy elderly people, and future research needs to pay more attention to the effects of sarcopenia on the pharmacodynamics and pharmacokinetics of anesthetics, to provide a reasonable basis through which clinicians can achieve precise anesthesia.

8. Author contributions

CL and CY devised the structure of the review. The manuscript was drafted by YS, and YS and LZ reviewed the manuscript. EY and LY edited the manuscript. All authors have read and agreed to submit the manuscript.

9. Ethics approval and consent to participate

Not applicable.

10. Acknowledgment

Not applicable.

11. Funding

This study was funded by the National Natural Science Foundation of China (No. 81703482 and 81974171 to C.Y., 82070405 to L.Y.) and the Science and Technology Support (Social Development) Project of Bureau of Science and Technology of Changzhou (No. CE20195044 to L.Y.).

12. Conflict of interest

The authors declare no conflict of interest.

Abbreviations

AChRs, acetylcholine receptors; ASA, American Society of Anesthesiologists; ASM, appendicular skeletal muscle mass; AWGS, Asian Working Group for Sarcopenia; BIA, bioelectrical impedance analysis; CT, computed tomography; DXA, dual-energy X-ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People; F, female; GH, growth hormone; ICU, intensive care unit; IGF-1, insulin-like growth factor-1; IL-1, interleukin 1; IL-6, interleukin 6; LSMM, low skeletal muscle mass; M, male; MAC, minimal alveolar concentration; MQC, mitochondrial quality control; MRI, magnetic resonance imaging; NF-κB, nuclear factor-κB; NMJ, neuromuscular junction; PGC-1α, peroxisome proliferator-activated receptor-gamma coactivator 1 alpha; ROS, reactive oxygen species; SPPB, Short Physical Performance Battery; TNF-α, tumor necrosis factor-alpha; TUG, timed-up-and-go; TWEAK, TNF-α like weak inducer of apoptosis.

References
  • [1] Rosenberg IH. Sarcopenia: Origins and Clinical Relevance. the Journal of Nutrition. 1997; 127: 990S–991S.
  • [2] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019; 48: 601–601.
  • [3] Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association. 2020; 21: 300–307.e2.
  • [4] Landi F, Cruz-Jentoft AJ, Liperoti R, Russo A, Giovannini S, Tosato M, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age and Ageing. 2013; 42: 203–209.
  • [5] Legrand D, Vaes B, Matheï C, Swine C, Degryse J. The prevalence of sarcopenia in very old individuals according to the European consensus definition: insights from the BELFRAIL study. Age and Ageing. 2013; 42: 727–734.
  • [6] Patel HP, Syddall HE, Jameson K, Robinson S, Denison H, Roberts HC, et al. Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: findings from the Hertfordshire Cohort Study (HCS) Age and Ageing. 2013; 42: 378–384.
  • [7] Kim H, Hirano H, Edahiro A, Ohara Y, Watanabe Y, Kojima N, et al. Sarcopenia: Prevalence and associated factors based on different suggested definitions in community-dwelling older adults. Geriatrics & Gerontology International. 2016; 16: 110–122.
  • [8] Yu R, Leung J, Woo J. Incremental predictive value of sarcopenia for incident fracture in an elderly Chinese cohort: results from the Osteoporotic Fractures in Men (MrOs) Study. Journal of the American Medical Directors Association. 2014; 15: 551–558.
  • [9] Huang C, Hwang A, Liu L, Lee W, Chen L, Peng L, et al. Association of Dynapenia, Sarcopenia, and Cognitive Impairment among Community-Dwelling Older Taiwanese. Rejuvenation Research. 2016; 19: 71–78.
  • [10] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and Ageing. 2010; 39: 412–423.
  • [11] Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. Journal of Cachexia, Sarcopenia and Muscle. 2016; 7: 512–514.
  • [12] Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature Reviews Endocrinology. 2018; 14: 513–537.
  • [13] Batsis JA, Mackenzie TA, Emeny RT, Lopez-Jimenez F, Bartels SJ. Low Lean Mass with and without Obesity, and Mortality: Results from the 1999–2004 National Health and Nutrition Examination Survey. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2017; 72: 1445–1451.
  • [14] Shi B, Liu S, Chen J, Liu J, Luo Y, Long L, et al. Sarcopenia is Associated with Perioperative Outcomes in Gastric Cancer Patients Undergoing Gastrectomy. Annals of Nutrition and Metabolism. 2019; 75: 213–222.
  • [15] Hirase T, Haghshenas V, Bratescu R, Dong D, Kuo PH, Rashid A, et al. Sarcopenia predicts perioperative adverse events following complex revision surgery for the thoracolumbar spine. The Spine Journal. 2021; 21: 1001–1009.
  • [16] Ooi PH, Hager A, Mazurak VC, Dajani K, Bhargava R, Gilmour SM, et al. Sarcopenia in Chronic Liver Disease: Impact on Outcomes. Liver Transplantation. 2019; 25: 1422–1438.
  • [17] Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019; 393: 2636–2646.
  • [18] Woodrow G. Body composition analysis techniques in the aged adult: indications and limitations. Current Opinion in Clinical Nutrition and Metabolic Care. 2009; 12: 8–14.
  • [19] Mueller N, Murthy S, Tainter CR, Lee J, Riddell K, Fintelmann FJ, et al. Can Sarcopenia Quantified by Ultrasound of the Rectus Femoris Muscle Predict Adverse Outcome of Surgical Intensive Care Unit Patients as well as Frailty? A Prospective, Observational Cohort Study. Annals of Surgery. 2016; 264: 1116–1124.
  • [20] Ticinesi A, Meschi T, Narici MV, Lauretani F, Maggio M. Muscle Ultrasound and Sarcopenia in Older Individuals: A Clinical Perspective. Journal of the American Medical Directors Association. 2017; 18: 290–300.
  • [21] Picca A, Calvani R, Cesari M, Landi F, Bernabei R, Coelho-Júnior HJ, et al. Biomarkers of Physical Frailty and Sarcopenia: Coming up to the Place? International Journal of Molecular Sciences. 2020; 21: 5635.
  • [22] Badawi Y, Nishimune H. Impairment Mechanisms and Intervention Approaches for Aged Human Neuromuscular Junctions. Frontiers in Molecular Neuroscience. 2020; 13: 211.
  • [23] Larsson L, Degens H, Li M, Salviati L, Lee YI, Thompson W, et al. Sarcopenia: Aging-Related Loss of Muscle Mass and Function. Physiological Reviews. 2019; 99: 427–511.
  • [24] Rowan SL, Rygiel K, Purves-Smith FM, Solbak NM, Turnbull DM, Hepple RT. Denervation causes fiber atrophy and myosin heavy chain co-expression in senescent skeletal muscle. PloS one. 2012; 7: e29082.
  • [25] Chai RJ, Vukovic J, Dunlop S, Grounds MD, Shavlakadze T. Striking denervation of neuromuscular junctions without lumbar motoneuron loss in geriatric mouse muscle. PloS one. 2011; 6: e28090.
  • [26] Dumont NA, Bentzinger CF, Sincennes M, Rudnicki MA. Satellite Cells and Skeletal Muscle Regeneration. Comprehensive Physiology. 2015; 5: 1027–1059.
  • [27] Lexell J. Human aging, muscle mass, and fiber type composition. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 1995; 50 Spec No: 11–16.
  • [28] Verdijk LB, Snijders T, Drost M, Delhaas T, Kadi F, van Loon LJC. Satellite cells in human skeletal muscle; from birth to old age. Age. 2014; 36: 545–547.
  • [29] Almada AE, Wagers AJ. Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease. Nature Reviews. Molecular Cell Biology. 2016; 17: 267–279.
  • [30] Bao Z, Cui C, Chow SK, Qin L, Wong RMY, Cheung WH. AChRs Degeneration at NMJ in Aging-Associated Sarcopenia-A Systematic Review. Frontiers in Aging Neuroscience. 2020; 12: 454.
  • [31] Ham DJ, Börsch A, Lin S, Thürkauf M, Weihrauch M, Reinhard JR, et al. The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia. Nature Communications. 2020; 11: 4510.
  • [32] Romanello V, Sandri M. Mitochondrial Quality Control and Muscle Mass Maintenance. Frontiers in physiology. 2015; 6: 422.
  • [33] Calvani R, Joseph A, Adhihetty PJ, Miccheli A, Bossola M, Leeuwenburgh C, et al. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. Biological Chemistry. 2013; 394: 393–414.
  • [34] Pickles S, Vigié P, Youle RJ. Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance. Current Biology. 2018; 28: R170–R185.
  • [35] Yoo S, Jung Y. A Molecular Approach to Mitophagy and Mitochondrial Dynamics. Molecules and Cells. 2018; 41: 18–26.
  • [36] Eisner V, Lenaers G, Hajnóczky G. Mitochondrial fusion is frequent in skeletal muscle and supports excitation-contraction coupling. The Journal of Cell Biology. 2014; 205: 179–195.
  • [37] Twig G, Elorza A, Molina AJA, Mohamed H, Wikstrom JD, Walzer G, et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. The EMBO Journal. 2008; 27: 433–446.
  • [38] Twig G, Hyde B, Shirihai OS. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochimica Et Biophysica Acta (BBA)-Bioenergetics. 2008; 1777: 1092–1097.
  • [39] Romanello V. The Interplay between Mitochondrial Morphology and Myomitokines in Aging Sarcopenia. International Journal of Molecular Sciences. 2020; 22: 91.
  • [40] Huang D, Fan S, Chen X, Yan X, Zhang X, Ma B, et al. Nrf2 deficiency exacerbates frailty and sarcopenia by impairing skeletal muscle mitochondrial biogenesis and dynamics in an age-dependent manner. Experimental Gerontology. 2019; 119: 61–73.
  • [41] Sharma A, Smith HJ, Yao P, Mair WB. Causal roles of mitochondrial dynamics in longevity and healthy aging. EMBO Reports. 2019; 20: e48395.
  • [42] Rajawat YS, Hilioti Z, Bossis I. Aging: Central role for autophagy and the lysosomal degradative system. Ageing Research Reviews. 2009; 8: 199–213.
  • [43] García-Prat L, Martínez-Vicente M, Perdiguero E, Ortet L, Rodríguez-Ubreva J, Rebollo E, et al. Autophagy maintains stemness by preventing senescence. Nature. 2016; 529: 37–42.
  • [44] Gonzalez-Freire M, Scalzo P, D’Agostino J, Moore ZA, Diaz-Ruiz A, Fabbri E, et al. Skeletal muscle ex vivo mitochondrial respiration parallels decline in vivo oxidative capacity, cardiorespiratory fitness, and muscle strength: The Baltimore Longitudinal Study of Aging. Aging Cell. 2018; 17: e12725.
  • [45] Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. International journal of molecular sciences. 2010; 11: 1509–1526.
  • [46] Sorensen JC, Cheregi BD, Timpani CA, Nurgali K, Hayes A, Rybalka E. Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting? Cancer Chemotherapy and Pharmacology. 2016; 78: 673–683.
  • [47] Liguori I, Russo G, Aran L, Bulli G, Curcio F, Della-Morte D, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. Clinical Interventions in Aging. 2018; 13: 913–927.
  • [48] Gonzalez-Freire M, de Cabo R, Studenski SA, Ferrucci L. The Neuromuscular Junction: Aging at the Crossroad between Nerves and Muscle. Frontiers in Aging Neuroscience. 2014; 6: 208.
  • [49] Popov L. Mitochondrial biogenesis: an update. Journal of Cellular and Molecular Medicine. 2020; 24: 4892–4899.
  • [50] Gill JF, Santos G, Schnyder S, Handschin C. PGC-1α affects aging-related changes in muscle and motor function by modulating specific exercise-mediated changes in old mice. Aging Cell. 2018; 17: e12697.
  • [51] Cannavino J, Brocca L, Sandri M, Grassi B, Bottinelli R, Pellegrino MA. The role of alterations in mitochondrial dynamics and PGC-1α over-expression in fast muscle atrophy following hindlimb unloading. The Journal of Physiology. 2015; 593: 1981–1995.
  • [52] Joseph A, Adhihetty PJ, Buford TW, Wohlgemuth SE, Lees HA, Nguyen LM, et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell. 2012; 11: 801–809.
  • [53] Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Research Reviews. 2019; 56: 100980.
  • [54] Li C, Yu K, Shyh-Chang N, Li G, Jiang L, Yu S, et al. Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention. Journal of Cachexia, Sarcopenia and Muscle. 2019; 10: 586–600.
  • [55] Bano G, Trevisan C, Carraro S, Solmi M, Luchini C, Stubbs B, et al. Inflammation and sarcopenia: a systematic review and meta-analysis. Maturitas. 2017; 96: 10–15.
  • [56] Jo E, Lee S, Park B, Kim J. Potential mechanisms underlying the role of chronic inflammation in age-related muscle wasting. Aging Clinical and Experimental Research. 2012; 24: 412–422.
  • [57] Chhetri JK, de Souto Barreto P, Fougère B, Rolland Y, Vellas B, Cesari M. Chronic inflammation and sarcopenia: a regenerative cell therapy perspective. Experimental Gerontology. 2018; 103: 115–123.
  • [58] Yu J, Lee M. Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance. Archives of Pharmacal Research. 2016; 39: 1503–1518.
  • [59] Remels AH, Gosker HR, Schrauwen P, Hommelberg PP, Sliwinski P, Polkey M, et al. TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? The FASEB Journal. 2010; 24: 5052–5062.
  • [60] Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. The International Journal of Biochemistry & Cell Biology. 2013; 45: 2288–2301.
  • [61] Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging. 2012; 4: 166–175.
  • [62] Roubenoff R. Sarcopenic obesity: does muscle loss cause fat gain? Lessons from rheumatoid arthritis and osteoarthritis. Annals of the New York Academy of Sciences. 2000; 904: 553–557.
  • [63] Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Research Reviews. 2017; 35: 200–221.
  • [64] Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. Sarcopenic obesity: a new category of obesity in the elderly. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD. 2008; 18: 388–395.
  • [65] Apostolopoulos V, de Courten MPJ, Stojanovska L, Blatch GL, Tangalakis K, de Courten B. The complex immunological and inflammatory network of adipose tissue in obesity. Molecular Nutrition &Amp; Food Research. 2016; 60: 43–57.
  • [66] Rivas DA, McDonald DJ, Rice NP, Haran PH, Dolnikowski GG, Fielding RA. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2016; 310: R561–R569.
  • [67] Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration. Frontiers in Physiology. 2013; 4: 371.
  • [68] Tumova J, Andel M, Trnka J. Excess of free fatty acids as a cause of metabolic dysfunction in skeletal muscle. Physiological Research. 2016; 65: 193–207.
  • [69] Gysel T, Tonoli C, Pardaens S, Cambier D, Kaufman J, Zmierczak H, et al. Lower insulin sensitivity is related to lower relative muscle cross-sectional area, lower muscle density and lower handgrip force in young and middle aged non-diabetic men. Journal of Musculoskeletal & Neuronal Interactions. 2016; 16: 302–309.
  • [70] Stinkens R, Goossens GH, Jocken JWE, Blaak EE. Targeting fatty acid metabolism to improve glucose metabolism. Obesity Reviews. 2015; 16: 715–757.
  • [71] Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of Nutrition, Health & Aging. 2018; 22: 1148–1161.
  • [72] Da Boit M, Sibson R, Meakin JR, Aspden RM, Thies F, Mangoni AA, et al. Sex differences in the response to resistance exercise training in older people. Physiological Reports. 2016; 4: e12834.
  • [73] Goodpaster BH, Chomentowski P, Ward BK, Rossi A, Glynn NW, Delmonico MJ, et al. Effects of physical activity on strength and skeletal muscle fat infiltration in older adults: a randomized controlled trial. Journal of Applied Physiology. 2008; 105: 1498–1503.
  • [74] Ziaaldini MM, Marzetti E, Picca A, Murlasits Z. Biochemical Pathways of Sarcopenia and their Modulation by Physical Exercise: A Narrative Review. Frontiers in Medicine. 2017; 4: 167.
  • [75] Beckwée D, Delaere A, Aelbrecht S, Baert V, Beaudart C, Bruyere O, et al. Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. The Journal of Nutrition, Health & Aging. 2019; 23: 494–502.
  • [76] Lichtenberg T, von Stengel S, Sieber C, Kemmler W. The Favorable Effects of a High-Intensity Resistance Training on Sarcopenia in Older Community-Dwelling Men with Osteosarcopenia: The Randomized Controlled FrOST Study. Clinical interventions in aging. 2019; 14: 2173.
  • [77] Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Current Opinion in Clinical Nutrition and Metabolic Care. 2004; 7: 405–410.
  • [78] Robinson SM, Reginster JY, Rizzoli R, Shaw SC, Kanis JA, Bautmans I, et al. Does nutrition play a role in the prevention and management of sarcopenia? Clinical Nutrition. 2018; 37: 1121–1132.
  • [79] Borack MS, Volpi E. Efficacy and Safety of Leucine Supplementation in the Elderly. the Journal of Nutrition. 2016; 146: 2625S–2629S.
  • [80] Muir SW, Montero-Odasso M. Effect of Vitamin D Supplementation on Muscle Strength, Gait and Balance in Older Adults: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society. 2011; 59: 2291–2300.
  • [81] Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. Journal of the American Medical Directors Association. 2015; 16: 740–747.
  • [82] Kim HK, Suzuki T, Saito K, Yoshida H, Kobayashi H, Kato H, et al. Effects of exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly Japanese sarcopenic women: a randomized controlled trial. Journal of the American Geriatrics Society. 2012; 60: 16–23.
  • [83] Denison HJ, Cooper C, Sayer AA, Robinson SM. Prevention and optimal management of sarcopenia: a review of combined exercise and nutrition interventions to improve muscle outcomes in older people. Clinical Interventions in Aging. 2015; 10: 859–869.
  • [84] Deutz NEP, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clinical Nutrition. 2014; 33: 929–936.
  • [85] Burd NA, West DWD, Moore DR, Atherton PJ, Staples AW, Prior T, et al. Enhanced amino acid sensitivity of myofibrillar protein synthesis persists for up to 24 h after resistance exercise in young men. The Journal of Nutrition. 2011; 141: 568–573.
  • [86] Nabuco HCG, Tomeleri CM, Sugihara Junior P, Fernandes RR, Cavalcante EF, Antunes M, et al. Effects of Whey Protein Supplementation Pre- or Post-Resistance Training on Muscle Mass, Muscular Strength, and Functional Capacity in Pre-Conditioned Older Women: A Randomized Clinical Trial. Nutrients. 2018; 10: 563.
  • [87] Hardee JP, Lynch GS. Current pharmacotherapies for sarcopenia. Expert Opinion on Pharmacotherapy. 2019; 20: 1645–1657.
  • [88] Wolfe R, Ferrando A, Sheffield-Moore M, Urban R. Testosterone and muscle protein metabolism. Mayo Clinic Proceedings. 2000; 75 Suppl: S55–S60.
  • [89] Kovacheva EL, Hikim APS, Shen R, Sinha I, Sinha-Hikim I. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology. 2010; 151: 628–638.
  • [90] Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clinic Proceedings. 2015; 90: 224–251.
  • [91] Morley JE. Pharmacologic Options for the Treatment of Sarcopenia. Calcified Tissue International. 2016; 98: 319–333.
  • [92] Sumukadas D, Witham MD, Struthers AD, McMurdo MET. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ: Canadian Medical Association Journal. 2007; 177: 867–874.
  • [93] Weerink LBM, Hoorn A, Leeuwen BL, Bock GH. Low skeletal muscle mass and postoperative morbidity in surgical oncology: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle. 2020; 11: 636–649.
  • [94] Bokshan SL, Han AL, DePasse JM, Eltorai AEM, Marcaccio SE, Palumbo MA, et al. Effect of Sarcopenia on Postoperative Morbidity and Mortality after Thoracolumbar Spine Surgery. Orthopedics. 2016; 39: e1159–e1164.
  • [95] Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Nagatsuma Y, Nakayama T, et al. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2016; 19: 986–993.
  • [96] Simonsen C, de Heer P, Bjerre ED, Suetta C, Hojman P, Pedersen BK, et al. Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology. Annals of Surgery. 2018; 268: 58–69.
  • [97] Kuwada K, Kuroda S, Kikuchi S, Yoshida R, Nishizaki M, Kagawa S, et al. Sarcopenia and Comorbidity in Gastric Cancer Surgery as a Useful Combined Factor to Predict Eventual Death from other Causes. Annals of Surgical Oncology. 2018; 25: 1160–1166.
  • [98] Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status - historical perspectives and modern developments. Anaesthesia. 2019; 74: 373–379.
  • [99] Carey EJ, Lai JC, Sonnenday C, Tapper EB, Tandon P, Duarte-Rojo A, et al. A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. Hepatology. 2019; 70: 1816–1829.
  • [100] Yamamoto K, Nagatsuma Y, Fukuda Y, Hirao M, Nishikawa K, Miyamoto A, et al. Effectiveness of a preoperative exercise and nutritional support program for elderly sarcopenic patients with gastric cancer. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017; 20: 913–918.
  • [101] Ahn EJ, Kim HJ, Kim KW, Choi HR, Kang H, Bang SR. Comparison of general anaesthesia and regional anaesthesia in terms of mortality and complications in elderly patients with hip fracture: a nationwide population-based study. BMJ Open. 2019; 9: e029245.
  • [102] Wilson JM, Farley KX, Bradbury TL, Guild GN. Is Spinal Anesthesia Safer than General Anesthesia for Patients Undergoing Revision THA? Analysis of the ACS-NSQIP Database. Clinical Orthopaedics & Related Research. 2020; 478: 80–87.
  • [103] Memtsoudis SG, Cozowicz C, Bekeris J, Bekere D, Liu J, Soffin EM, et al. Anaesthetic care of patients undergoing primary hip and knee arthroplasty: consensus recommendations from the International Consensus on Anaesthesia-Related Outcomes after Surgery group (ICAROS) based on a systematic review and meta-analysis. British Journal of Anaesthesia. 2019; 123: 269–287.
  • [104] Le-Wendling L, Bihorac A, Baslanti TO, Lucas S, Sadasivan K, Wendling A, et al. Regional anesthesia as compared with general anesthesia for surgery in geriatric patients with hip fracture: does it decrease morbidity, mortality, and health care costs? Results of a single-centered study. Pain Medicine. 2012; 13: 948–956.
  • [105] Moreira CC, Farber A, Kalish JA, Eslami MH, Didato S, Rybin D, et al. The effect of anesthesia type on major lower extremity amputation in functionally impaired elderly patients. Journal of Vascular Surgery. 2016; 63: 696–701.
  • [106] Griffiths R, Babu S, Dixon P, Freeman N, Hurford D, Kelleher E, et al. Guideline for the management of hip fractures 2020. Anaesthesia. 2021; 76: 225–237.
  • [107] McLachlan A, Hilmer S, Le Couteur D. Variability in Response to Medicines in Older People: Phenotypic and Genotypic Factors. Clinical Pharmacology & Therapeutics. 2009; 85: 431–433.
  • [108] Araújo AM, Machado HS, Falcão AC, Soares-da-Silva P. Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients. BMC Anesthesiology. 2019; 19: 180.
  • [109] Phillips AT, Deiner S, Mo Lin H, Andreopoulos E, Silverstein J, Levin MA. Propofol Use in the Elderly Population: Prevalence of Overdose and Association with 30-Day Mortality. Clinical Therapeutics. 2015; 37: 2676–2685.
  • [110] Steinmetz J, Rasmussen LS. The elderly and general anesthesia. Minerva Anestesiologica. 2010; 76: 745–752.
  • [111] Lee JM, Min G, Lee JM, Kim SH, Choi HS, Kim ES, et al. Efficacy and safety of etomidate-midazolam for screening colonoscopy in the elderly: a prospective double-blinded randomized controlled study. Medicine. 2018; 97: e10635.
  • [112] Hannam JA, Mitchell SJ, Cumin D, Frampton C, Merry AF, Moore MR, et al. Haemodynamic profiles of etomidate vs propofol for induction of anaesthesia: a randomised controlled trial in patients undergoing cardiac surgery. British Journal of Anaesthesia. 2019; 122: 198–205.
  • [113] Lee JM, Min G, Keum B, Lee JM, Kim SH, Choi HS, et al. Using Etomidate and Midazolam for Screening Colonoscopies Results in more Stable Hemodynamic Responses in Patients of all Ages. Gut and Liver. 2019; 13: 649–657.
  • [114] Griffiths R, Beech F, Brown A, Dhesi J, Foo I, Goodall J, et al. Peri-operative care of the elderly 2014: Association of Anaesthetists of Great Britain and Ireland. Anaesthesia. 2014; 69: 81–98.
  • [115] Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clinical Pharmacology and Therapeutics. 2003; 74: 102–112.
  • [116] McLachlan AJ, Bath S, Naganathan V, Hilmer SN, Le Couteur DG, Gibson SJ, et al. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. British Journal of Clinical Pharmacology. 2011; 71: 351–364.
  • [117] Inouye SK, Robinson T, Blaum C, Busby-Whitehead J, Boustani M, Chalian A, et al. Postoperative delirium in older adults: best practice statement from the American Geriatrics Society. Journal of the American College of Surgeons. 2015; 220: 136–148. e1.
  • [118] Scurrah A, Shiner CT, Stevens JA, Faux SG. Regional nerve blockade for early analgesic management of elderly patients with hip fracture - a narrative review. Anaesthesia. 2018; 73: 769–783.
  • [119] Guay J, Parker MJ, Griffiths R, Kopp SL. Peripheral Nerve Blocks for Hip Fractures: A Cochrane Review. Anesthesia and Analgesia. 2018; 126: 1695–1704.
  • [120] Leeper AD, Brandon PT, Morgan AVM, Cutts S, Cohen AMM. Fascia iliaca compartment block reduces morphine requirement pre-operatively for patients with fractured neck of femur. European Journal of Trauma and Emergency Surgery: Official Publication of the European Trauma Society. 2012; 38: 673–677.
  • [121] Pietraszewski P, Gaszyński T. Residual neuromuscular block in elderly patients after surgical procedures under general anaesthesia with rocuronium. Anaesthesiology Intensive Therapy. 2013; 45: 77–81.
  • [122] Zhao W, Yang M, Wu H, Yang L, Zhang X, Huang Y. Systematic Review and Meta-Analysis of the Association between Sarcopenia and Dysphagia. the Journal of Nutrition, Health & Aging. 2018; 22: 1003–1009.
  • [123] Fujishima I, Fujiu-Kurachi M, Arai H, Hyodo M, Kagaya H, Maeda K, et al. Sarcopenia and dysphagia: Position paper by four professional organizations. Geriatrics & Gerontology International. 2019; 19: 91–97.
  • [124] Xiaobo F, Jianjuan K, Yanlin W. Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. Brazilian Journal of Medical and Biological Research. 2012; 45: 676–680.
  • [125] Ornstein E, Lien CA, Matteo RS, Ostapkovich ND, Diaz J, Wolf KB. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. Anesthesiology. 1996; 84: 520–525.
  • [126] Arain SR, Kern S, Ficke DJ, Ebert TJ. Variability of duration of action of neuromuscular-blocking drugs in elderly patients. Acta Anaesthesiologica Scandinavica. 2005; 49: 312–315.
  • [127] Vuyk J. Pharmacodynamics in the elderly. Best Practice & Research Clinical Anaesthesiology. 2003; 17: 207–218.
  • [128] Hirsch NP. Neuromuscular junction in health and disease. British Journal of Anaesthesia. 2007; 99: 132–138.
  • [129] Blichfeldt-Lauridsen L, Hansen BD. Anesthesia and myasthenia gravis. Acta Anaesthesiologica Scandinavica. 2012; 56: 17–22.
  • [130] Sanfilippo M, Fierro G, Cavalletti MV, Biancari F, Vilardi V. Rocuronium in two myasthenic patients undergoing thymectomy. Acta Anaesthesiologica Scandinavica. 1997; 41: 1365–1366.
  • [131] Muckler VC, O’Brien JM, Matson SE, Rice AN. Perianesthetic Implications and Considerations for Myasthenia Gravis. Journal of PeriAnesthesia Nursing. 2019; 34: 4–15.
  • [132] Peng T, Chen W, Wu L, Chang Y, Kao T. Sarcopenia and cognitive impairment: a systematic review and meta-analysis. Clinical Nutrition. 2020; 39: 2695–2701.
  • [133] Needham MJ, Webb CE, Bryden DC. Postoperative cognitive dysfunction and dementia: what we need to know and do. British Journal of Anaesthesia. 2017; 119: i115–i125.
  • [134] Hiraoka A, Otsuka Y, Kawasaki H, Izumoto H, Ueki H, Kitahata S, et al. Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology. 2018; 33: 1271–1276.
  • [135] Mosk CA, van Vugt JLA, de Jonge H, Witjes CD, Buettner S, Ijzermans JN, et al. Low skeletal muscle mass as a risk factor for postoperative delirium in elderly patients undergoing colorectal cancer surgery. Clinical Interventions in Aging. 2018; 13: 2097.
Share and Cite
Yan Shi, Ling Zhou, Enshi Yan, Ling Yang, Chun Yang, Cunming Liu. Sarcopenia and perioperative management of elderly surgical patients. Frontiers in Bioscience-Landmark. 2021. 26(10); 882-894.